• Butt ZA, Shrestha N, Kuo M, Gesink D, Gilbert M, Wong J, et al. A Syndemic Approach to Asses the effect pf Substance Use and Social Disparties on the evloution of HIV/HCV infections in British Columbia. PLOS ONE. 2017. DOI:


  • Butt ZA, ShresthaN, Kuo M, Gesink D, Gilbert M, Wong J, A Yu, Alvarez M, Samji H, Buxton JA, Johnston JC, Cook CJ, Roth D, Consolacion T, Murti M, Ogilvie G, Balshaw R, Tyndall M, Krajden M, Janjua NZ and the BC-HTC Team. Social Disparities and c0-evolution of HIV/HCV infections, mental disorders and substance use: The British Columbia Hepatitis Testers Cohort. PLoS ONE 2017


  • Islam N, Krahden M, shoveller JA, Gustafson P, Gilbert M, Wong J, et al. Hepatitis C cross-genotype immunity and implications for vaccine development. Scientific Report 2017;12326. DOI:


  • Islam N, Krajden M, Shoveller J, Gustafafson P, Gilbert M, Wong J, Tyndall M, Janjua NZ and The BC_HTC Team. Re-clearance of hepatitis C: Role of previous clearance and reinfection with a heterologous genotype. Scientific Report 2017 DOI:10.1038/s41598-017-10190-8


  • Samji, H., Yu, A., Kuo, M., Alavi, M., Woods, R., Alvarez, M., Dore, G.J., Tyndall, M., Krajden, M., Janjua, N.Z., for the BC Hepatitis Testers Cohort Team, Late hepatitis B and C diagnosis in relation to disease decompensation and hepatocellular carcinoma development, Journal of Hepatology (2017), doi:


  • Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton JA, Wong J, Tyndall MW, Janjua NZ. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study. The Lancet Gastroenterology & Hepatology 2017;2(3)200-210. doi:
    Available from: The Lancet Gastroenterology & Hepatology


  • Janjua NZ, Kuo M, Chong M, Yu A, Alvarez M, Cook D, Armour R, Aiken C, Li K, Godfrey, Wong J, Gilbert M, Tyndall MW, Krajden M. Assessing hepatitis C burden and treatment effectiveness through the British Columbia Hepatitis Testers Cohort (BC-HTC): design and characteristics of linked and unlinked participants.  PLoS ONE 11(3): e0150176. March 2016. doi:10.1371/journal.pone.0150176
    Available from: PloS ONE


  • Janjua NZ, Yu A, Kuo M, Alvarez M, Cook D, Wong J, Tyndall MW, Krajden M. Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort. BMC Infect Dis. 2016 Jul 19;16:334. doi: 10.1186/s12879-016-1683-z
    Available from: BMC Infectious Diseases


  • Janjua NZ, Kuo M, Yu A, Alvarez M, Wong S, Cook D, Wong J, Grebely J, Butt ZA, Samji H, Ramji A, Tyndall MW, Krajden M. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC). EBioMedicine 2016;12:89–195  doi: 10.1016/j.ebiom.2016.08.035
    Available from: EBioMedicine


  • Janjua NZ, Chong M, Kuo M, Woods R, Wong J, Yoshida EM, Sherman M, Butt ZA, Samji H, Cook D, Yu A, Alvarez M, Tyndall M, Krajden M. Long-term effect of sustained virological response on hepatocellular carcinoma in patients with hepatitis C in Canada. Journal of Hepatology. 2016. doi:
    Available from: Journal of Hepatology


  • Islam N, Krajden M, Gilbert M, Gustafson P, Yu A, Kuo M, Chong M, Alvarez M, Wong J, Tyndall MW, Janjua NZ. Role of primary T-cell immunodeficiency and hepatitis B coinfection on spontaneous clearance of Hepatitis C: The BC Hepatitis Testers Cohort. J Viral Hepat. 2016. doi: 10.1111/jvh.1265
    Available from: Journal of Viral Hepatology


  • Janjua NZ, Islam N, Wong J, Yoshida E, Ramji A, Samji H, et al. Shift in disparities in Hepatitis C treatment form interferon to DAA: A population-based cohort study. J Viral. 2016. In Press